Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02552121 · OUTCOME

Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors · Source last updated 2021-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
hours
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1

Analysis population: Insufficient samples were taken in Cycle 2 and beyond to calculate PK parameters, therefore only Cycle 1 is reported. Cycle 1 is an overall value, calculated over the entire cycle.

Groups in this outcome

Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg

Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).

Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg

Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg3
Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg6

Reported measurements

Cycle 1
Values in hours · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg392.0243.256Not reportedNot reportedNot reported
Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg373.3666.290Not reportedNot reportedNot reported
Cycle 1 Day 1
Values in hours · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg44.568114.567Not reportedNot reportedNot reported
Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg32.001125.788Not reportedNot reportedNot reported
Cycle 1 Day 8
Values in hours · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg10.354165.509Not reportedNot reportedNot reported
Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg20.837106.094Not reportedNot reportedNot reported
Cycle 1 Day 15
Values in hours · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg54.51120.424Not reportedNot reportedNot reported
Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg32.53763.879Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        3.256
        value
        392.024
      2. group Id
        OG001
        spread
        6.290
        value
        373.366
    title
    Cycle 1
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        114.567
        value
        44.568
      2. group Id
        OG001
        spread
        125.788
        value
        32.001
    title
    Cycle 1 Day 1
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        165.509
        value
        10.354
      2. group Id
        OG001
        spread
        106.094
        value
        20.837
    title
    Cycle 1 Day 8
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        20.424
        value
        54.511
      2. group Id
        OG001
        spread
        63.879
        value
        32.537
    title
    Cycle 1 Day 15
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      6
    units
    Participants
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).
    id
    OG000
    title
    Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg
  2. description
    Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).
    id
    OG001
    title
    Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg
param Type
GEOMETRIC_MEAN
population Description
Insufficient samples were taken in Cycle 2 and beyond to calculate PK parameters, therefore only Cycle 1 is reported. Cycle 1 is an overall value, calculated over the entire cycle.
reporting Status
POSTED
time Frame
Before infusion, end of infusion (+15 minutes), and +2 hours post infusion on days 1, 8, and 15, +24 hours 1st infusion (Day 2), +24 hours 3rd infusion (Day 16), +72 hours 3rd infusion (Day 18), and +168 hours 3rd infusion (Day 22) of Cycle 1
title
Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)
type
SECONDARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice